Table 2.
Characteristics of the studies included in the meta-analysis.
| Study ID | Intervention | Control | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type (dose) | N | Age | BWB (kg) | WCB (cm) | BMIB (kg/m2) | Type (dose) | N | Age | BWB (kg) | WCB (cm) | BMIB (kg/m2) | |
| (BWC) | (WCC) | (BMIC) | (BWC) | (WCC) | (BMIC) | |||||||
| 1 | EXE (10 μg BID) | 14 | 28.2 ± 4.9 | 110.5 ± 26.8 (−3.2 ± 0.4) | 40.3 ± 8.9 (−1.0 ± 1.1) | MET (1000 mg BID) | 7 | 27.7 ± 5.8 | 113.4 ± 31.3 (−1.6 ± 0.8) | 43.3 ± 8.9 (−1.0 ± 1.1) | ||
| 2 | EXE (10 μg BID) + MET (1000 mg BID) | 14 | 32.1 ± 3.1 | 112.0 ± 35.8 (−6.0 ± 1.9) | 40.9 ± 8.9 (−1.7 ± 1.1) | MET (1000 mg BID) | 7 | 27.7 ± 5.8 | 113.4 ± 31.3 (−1.6 ± 0.8) | 43.3 ± 8.9 (−1.0 ± 1.1) | ||
| 3 | LIRA (1.2 mg QD) | 11 | 31.5 ± 6.4 | 108.9 ± 15.1 (−3.8 ± 3.7) | 124.9 ± 9.9 (−3.2 ± 2.9) | 39.3 ± 4.2 (−1.3 ± 1.3) | MET (1000 mg BID) | 7 | 31.3 ± 9.4 | 103.2 ± 6.3 (−1.2 ± 1.4) | 122.3 ± 7.0 (−1.6 ± 2.9) | 36.6 ± 3.5 (−0.5 ± 0.5) |
| 4 | LIRA (1.2 mg QD) + MET (1000 mg BID) | 11 | 31.1 ± 5.1 | 105.5 ± 20.6 (−6.5 ± 2.8) | 121.9 ± 17.7 (−5.5 ± 3.8) | 37.6 ± 5.1 (−2.4 ± 1.0) | MET (1000 mg BID) | 7 | 31.3 ± 9.4 | 103.2 ± 6.3 (−1.2 ± 1.4) | 122.3 ± 7.0 (−1.6 ± 2.9) | 36.6 ± 3.5 (−0.5 ± 0.5) |
| 5 | LIRA (1.2 mg QD) | 14 | 29.5 ± 7.7 | 113.7 ± 18.7 (−3.0 ± 3.4) | 128.5 ± 13.9 (−4.4 ± 5.0) | 41.6 ± 5.3 (−1.1 ± 1.1) | MET (1000 mg BID) | 14 | 25.3 ± 5.2 | 103.6 ± 19.7 (−2.3 ± 2.6) | 121.6 ± 17.1 (−2.6 ± 3.0) | 37.4 ± 6.4 (−0.9 ± 0.9) |
| 6 | LIRA (1.2 mg QD) | 14 | 30.7 ± 7.9 | 102.8 ± 16.3 (−3.1 ± 3.5) | 115.7 ± 12.5 (−3.1 ± 2.8) | 36.7 ± 5.6 (−1.1 ± 1.3) | MET (1000 mg BID) | 13 | 30.7 ± 7.9 | 108.3 ± 17.0 (−0.2 ± 1.8) | 120.5 ± 14.5 (0.8 ± 1.9) | 39.4 ± 6.9 (−0.1 ± 0.7) |
| 7 | EXE (10 μg BID) | 80 | 27.9 ± 2.7 | 73.0 ± 9.8 (−4.3 ± 1.3) | 93.0 ± 10.1 (−9.0 ± 3.8) | 29.2 ± 3.1 (−3.1 ± 1.4) | MET (1000 mg BID) | 78 | 27.7 ± 3.8 | 70.4 ± 4.6 (−2.3 ± 0.6) | 89.4 ± 6.6 (−5.0 ± 4.7) | 28.3 ± 1.9 (−1.0 ± 0.2) |
| 8 | LIRA (1.2 mg QD) + MET (1000 mg BID) | 14 | 30.1 ± 3.6 | 106.6 ± 11.7 (−7.5 ± 3.9) | 114.5 ± 9.9 (−11.7 ± 9.0) | 37.8 ± 3.0 (−2.7 ± 1.3) | MET (1000 mg BID) | 14 | 31.1 ± 4.7 | 99.6 ± 17.8 (−7.0 ± 6.0) | 108.8 ± 14.5 (−11.3 ± 9.2) | 35.5 ± 4.9 (−2.5 ± 2.0) |
BID: twice daily; QD: once daily; BWB: body weight baseline (kg); BWC: body weight changes (kg); WCB: waist circumference baseline (cm); WCC: waist circumference changes (cm); BMIB: body mass index baseline (kg/m2); BMIC: body mass index changes (kg/m2); EXE: exenatide; LIRA: liraglutide; MET: metformin.